Abstract
Background. In most patients with recurrent glioma chemotherapy is the only remaining treatment option. In general results of chemotherapy in these patients are poor, and trials on new regimens are indicated. Because relatively good results have been achieved with combinations of platin compounds and etoposide, we investigated a dose-intensified cisplatin regimen with oral etoposide.
Methods. Eligible patients, with recurrent glioma after surgery and radiation therapy were treated with two four week-cycles with cisplatin 70 mg/m2 on days 1, 8 and 15, combined with oral etoposide 50 mg daily on days 1–15. In responding or stabilized patients, treatment was continued with six four week-cycles of oral etoposide 50 mg/m2 on days 1–21. Toxicity was assessed using the NCI Common Toxicity Criteria, a 50% decrease in contrast enhancing area on MRI scan was considered a partial response. Time to progression was measured from the start of chemotherapy.
Results. Sixteen patients were included, 11 were progressive during or immediately after the induction cycles. Two patients achieved a partial response with a time to progression of 42 and 58 weeks. Three patients were stable for 11, 14 and 15 weeks respectively. Toxicity was modest.
Discussion. This dose-intensified cisplatin regimen did not result in a significant number of objective responses and even the number of ‘stable disease’ was small. Given the low response rate of this intensive treatment, we consider this intensive regimen inappropriate for these patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, Milojevic L, Djuric L, Mijatovic L: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study. J Clin Oncol 10: 1074–1077, 1992
Ameri A, Poisson M, Chauveinc L, Chen QM, Delattre JY: Treatment of carboplatin and etoposide: A phase II study. J Neuro-Oncol 32: 155–160, 1997
Buckner LC, Brown LD, Cascino TL, Gerstner JB, Krook JE, Westberg MW, Wiesenfeld M, O'Fallon JR, Scheithauer B: Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma. J Neuro-Oncol 9: 249–254, 1990
Tirelli U, D'Incalci M, Canetta R, Tumola S, Franchin G, Veronesi A, Galligioni E, Trovo MG, Rossi C, Grigoletto E: Etoposide (VP-16–213) in malignant brain tumors: A phase II study. J Clin Oncol 2: 432–437, 1984
Fulton D, Urtasun R, Forsyth P: Phase II study of prolonged oral therapy with etoposide (UP-16) for patients with recurrent malignant glioma. J Neuro-Oncol 27: 149–155, 1996
Warnick RE, Prados MD, Mack EE, Chandler KL, Doz F, Rabbitt JE, Malec MK: A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neuro-Oncol 19: 69–74, 1994
Prados MD, Warnick RE, Mack EE, Chandler KL, Rabbitt J, Page M, Malec M: Intravenous carboplatin for recurrent gliomas. Amer J Clin Oncol (CCT) 19: 609–612, 1996
Spence AM, Berger MS, Livingston RB, Ali-Osman F, Griffin B: Phase II evaluation of high-dose intravenous cisplatin for the treatment of adult malignant gliomas recurrent after chloroethylnitrosurea failure. J Neuro-Oncol 12: 187–191, 1992
Planting AST, Van der Burg MEL, de Boer-Dennert M, Stoter G, Verweij J: Phase I study of weekly high dose cisplatin combined with long term oral etoposide in advanced solid tumors. Ann Oncol 6: 190–192, 1994
Planting AST, Van der Burg MEL, Goey SH, Schellens JHM, Van den Bent MJ, de Boer-Dennert M, Stoter G, Verweij J: Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann Oncol 6: 613–615, 1995
Planting AST, Kho GS, Van der Burg MEL, Goey SH, Schellens JHM, Van den Bent MJ, Van der Gaast A, de Boer-Dennert M, Stoter G, Verweij J: A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 40: 347–352, 1997
Planting AST, Van der Burg MEL, Van den Bent MJ, de Boer-Dennert M, Stoter G, Verweij J: Phase II study of as short course of weekly high-dose cisplatin combined with oral etoposide in metastatic colorectal carcinoma. Brit J Cancer 73: 1265–1267, 1996
Walker RW, Cairncross JG, Posner JB: Cerebral herniation in patients receiving cisplatin. J Neuro-Oncol 6: 61–65, 1988
Hildebrand J, De Witte O, Sahmoud T: Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine. J Neuro-Oncol 37: 155–160, 1998
Levin V, Yung A, Prados M, Poisson M, Rosenfeld S, Brada M, Friedman H, Albright R, Olson J, Bruner J,YueN, Dugan M: Phase II study of temodal (temozolomide) at first relapse in anaplastic astrocytoma (AA) patients. J Neuro-Oncol 35: 185, 1997 (abstract)
Yung A, Albright R, Olson J, Frederick R, Fink D, Prados M, Brada M, Spence AM, Bruner J, Yue N, Dugan M: Randomized trial of temodal versusprocarbazine in glioblastoma multiforme at first relapse. J Neuro-Oncol 39: 102, 1998 (abstract)
Sanson M, Ameri A, Monjour A, Sahmoud T, Ronchin P, Poisson M, Delattre JY: Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: A phase II study. Eur J Cancer 32A: 2229–2235, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van den Bent, M., Pronk, L., Sillevis Smitt, P. et al. Phase II Study of Weekly Dose-intensified Cisplatin Chemotherapy with Oral Etoposide in Recurrent Glioma. J Neurooncol 44, 59–64 (1999). https://doi.org/10.1023/A:1006201909435
Issue Date:
DOI: https://doi.org/10.1023/A:1006201909435